TG Therapeutics Inc vs Twist Bioscience Corp — how do they compare? TG Therapeutics Inc trades at $54.06 (market cap $8.26B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: TG Therapeutics Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| TGTX | TWST | |
|---|---|---|
Market Cap | $8.26B | $5.45B |
Sector | Health | Health |
52-Week High | $59.06 | $102.88 |
52-Week Low | $26.39 | $24.16 |
Enterprise Value | $8.50B | $5.37B |
Trailing returns across standard periods
Latest headlines on both assets
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →